Patents Assigned to Signature Therapeutics, Inc.
-
Patent number: 11400062Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an amphetamine prodrug that provides enzymatically-controlled release of amphetamine or an amphetamine analog. The composition can further comprise an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of amphetamine or the amphetamine analog from the amphetamine prodrug so as to attenuate enzymatic cleavage of the amphetamine prodrug.Type: GrantFiled: October 17, 2019Date of Patent: August 2, 2022Assignee: Signature Therapeutics, Inc.Inventors: Thomas E. Jenkins, Craig O. Husfeld, Julie D. Seroogy, Jonathan W. Wray
-
Patent number: 11179355Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an amphetamine prodrug that provides enzymatically-controlled release of amphetamine or an amphetamine analog. The composition can further comprise an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of amphetamine or the amphetamine analog from the amphetamine prodrug so as to attenuate enzymatic cleavage of the amphetamine prodrug.Type: GrantFiled: February 12, 2016Date of Patent: November 23, 2021Assignee: Signature Therapeutics, Inc.Inventors: Thomas E. Jenkins, Craig O. Husfeld, Julie D. Seroogy, Jonathan W. Wray
-
Patent number: 10028945Abstract: A method of providing a patient with controlled release of ketone-containing opioid using a prodrug capable, upon enzymatic activation and intramolecular cyclization, of releasing the ketone-containing opioid is disclosed. The disclosure also provides such prodrug compounds and pharmaceutical compositions comprising such compounds. Such pharmaceutical compositions can optionally include an enzyme inhibitor that interacts with the enzyme(s) to mediate the enzymatically-controlled release of the ketone-containing opioid from the prodrug so as to modify enzymatic cleavage of the prodrug. Also included are methods to use such compounds and pharmaceutical compositions.Type: GrantFiled: October 5, 2016Date of Patent: July 24, 2018Assignee: Signature Therapeutics, Inc.Inventors: Thomas E. Jenkins, Craig O. Husfeld, Julie D. Seroogy, Jonathan W. Wray
-
Patent number: 9585963Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an opioid prodrug that provides enzymatically-controlled release of an opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the opioid from the opioid prodrug so as to attenuate enzymatic cleavage of the opioid prodrug.Type: GrantFiled: April 21, 2015Date of Patent: March 7, 2017Assignee: Signature Therapeutics, Inc.Inventors: Thomas E. Jenkins, Craig O. Husfeld, Julie D. Seroogy, Jonathan W. Wray
-
Patent number: 9534014Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenolic opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the phenolic opioid from the prodrug so as to attenuate enzymatic cleavage of the prodrug.Type: GrantFiled: June 30, 2014Date of Patent: January 3, 2017Assignee: Signature Therapeutics, Inc.Inventors: Thomas E. Jenkins, Julie D. Seroogy, Jonathan W. Wray
-
Patent number: 9499581Abstract: The embodiments provide Compound KC-8, N-1-[3-(oxycodone-6-enol-carbonyl-methyl-amino)-2,2-dimethyl-propylamine]-arginine-glycine-malonic acid, or acceptable salts, solvates, and hydrates thereof. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug, Compound KC-8, that provides controlled release of oxycodone. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of oxycodone from the prodrug so as to attenuate enzymatic cleavage of the prodrug.Type: GrantFiled: January 9, 2015Date of Patent: November 22, 2016Assignee: Signature Therapeutics, Inc.Inventors: Thomas E. Jenkins, Craig O. Husfeld
-
Patent number: 9493477Abstract: A method of providing a patient with controlled release of ketone-containing opioid using a prodrug capable, upon enzymatic activation and intramolecular cyclization, of releasing the ketone-containing opioid is disclosed. The disclosure also provides such prodrug compounds and pharmaceutical compositions comprising such compounds. Such pharmaceutical compositions can optionally include an enzyme inhibitor that interacts with the enzyme(s) to mediate the enzymatically-controlled release of the ketone-containing opioid from the prodrug so as to modify enzymatic cleavage of the prodrug. Also included are methods to use such compounds and pharmaceutical compositions.Type: GrantFiled: April 21, 2010Date of Patent: November 15, 2016Assignee: Signature Therapeutics, Inc.Inventors: Thomas E. Jenkins, Craig O. Husfeld, Julie D. Seroogy, Jonathan W. Wray
-
Patent number: 9238020Abstract: A method of providing a patient with controlled release of tapentadol using a prodrug capable, upon enzymatic activation and intramolecular cyclization, of releasing tapentadol is disclosed. The disclosure also provides such prodrug compounds and pharmaceutical compositions comprising such compounds. Such pharmaceutical compositions can optionally include an enzyme inhibitor that interacts with the enzyme(s) to mediate the enzymatically-controlled release of tapentadol from the prodrug so as to modify enzymatic cleavage of the prodrug. Also included are methods to use such compounds and pharmaceutical compositions.Type: GrantFiled: October 14, 2010Date of Patent: January 19, 2016Assignee: Signature Therapeutics, Inc.Inventors: Thomas E. Jenkins, Julie D. Seroogy, Jonathan W. Wray
-
Patent number: 9139612Abstract: The embodiments provide prodrug compounds of Formulae I-XVII. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug compound of Formulae I-XVII that provides controlled release of an active agent. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of an active agent from the prodrug so as to attenuate enzymatic cleavage of the prodrug.Type: GrantFiled: March 8, 2012Date of Patent: September 22, 2015Assignee: Signature Therapeutics, Inc.Inventors: Thomas E. Jenkins, Craig O. Husfeld
-
Patent number: 9095627Abstract: The embodiments provide prodrug compounds of Formulae I-XV. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug compound of Formulae I-XV that provides controlled release of an opioid. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of an opioid from the prodrug so as to attenuate enzymatic cleavage of the prodrug.Type: GrantFiled: January 28, 2014Date of Patent: August 4, 2015Assignee: Signature Therapeutics, Inc.Inventors: Thomas E. Jenkins, Craig O. Husfeld
-
Patent number: 9040032Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an opioid prodrug that provides enzymatically-controlled release of an opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the opioid from the opioid prodrug so as to attenuate enzymatic cleavage of the opioid prodrug.Type: GrantFiled: November 27, 2012Date of Patent: May 26, 2015Assignee: Signature Therapeutics, Inc.Inventors: Thomas E. Jenkins, Craig O. Husfeld, Julie D. Seroogy, Jonathan W. Wray
-
Patent number: 9023860Abstract: Pro-drugs containing an electron withdrawing substituent, as defined in the specification, are useful in a method for providing a patient with post administration-activated, controlled release of a biologically active compound.Type: GrantFiled: November 26, 2008Date of Patent: May 5, 2015Assignee: Signature Therapeutics, Inc.Inventor: Thomas E. Jenkins
-
Patent number: 8962547Abstract: The embodiments provide Compound KC-8, N-1-[3-(oxycodone-6-enol-carbonyl-methyl-amino)-2,2-dimethyl-propylamine]-arginine-glycine-malonic acid, or acceptable salts, solvates, and hydrates thereof. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug, Compound KC-8, that provides controlled release of oxycodone. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of oxycodone from the prodrug so as to attenuate enzymatic cleavage of the prodrug.Type: GrantFiled: September 24, 2013Date of Patent: February 24, 2015Assignee: Signature Therapeutics, Inc.Inventors: Thomas E. Jenkins, Craig O. Husfeld
-
Patent number: 8921418Abstract: A method of providing a patient with controlled release of a phenolic opioid using a prodrug capable, upon enzymatic activation, of releasing the phenolic opioid through intra-molecular cyclization leading to formation of a cyclic urea, carbamate or thiocarbamate.Type: GrantFiled: June 1, 2012Date of Patent: December 30, 2014Assignee: Signature Therapeutics, Inc.Inventors: Thomas E. Jenkins, Aleksandr Kolesnikov
-
Patent number: 8871815Abstract: A (?)-stereoisomer of formula (I): wherein X is H or F; or a pharmaceutically acceptable salt or prodrug thereof, useful as an anesthetic.Type: GrantFiled: September 23, 2013Date of Patent: October 28, 2014Assignee: Signature Therapeutics, Inc.Inventor: Thomas E. Jenkins
-
Patent number: 8802681Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenolic opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the phenolic opioid from the prodrug so as to attenuate enzymatic cleavage of the prodrug.Type: GrantFiled: October 16, 2009Date of Patent: August 12, 2014Assignee: Signature Therapeutics, Inc.Inventors: Thomas E. Jenkins, Julie D. Seroogy, Jonathan W. Wray
-
Publication number: 20140206773Abstract: A (?)-stereoisomer of formula (I): wherein X is H or F; or a pharmaceutically acceptable salt or prodrug thereof, useful as an anesthetic.Type: ApplicationFiled: September 23, 2013Publication date: July 24, 2014Applicant: Signature Therapeutics, Inc.Inventor: Thomas E. Jenkins
-
Publication number: 20140162935Abstract: The embodiments provide Compound KC-8, N-1-[3-(oxycodone-6-enol-carbonyl-methyl-amino)-2,2-dimethyl-propylamine]-arginine-glycine-malonic acid, or acceptable salts, solvates, and hydrates thereof. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug, Compound KC-8, that provides controlled release of oxycodone. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of oxycodone from the prodrug so as to attenuate enzymatic cleavage of the prodrug.Type: ApplicationFiled: September 24, 2013Publication date: June 12, 2014Applicant: Signature Therapeutics, Inc.Inventors: Thomas E. Jenkins, Craig O. Husfeld
-
Publication number: 20140121152Abstract: The embodiments provide prodrug compounds of Formulae I-XVII. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug compound of Formulae I-XVII that provides controlled release of an active agent. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of an active agent from the prodrug so as to attenuate enzymatic cleavage of the prodrug.Type: ApplicationFiled: March 8, 2012Publication date: May 1, 2014Applicant: Signature Therapeutics, Inc.Inventors: Thomas E. Jenkins, Craig O. Husfeld
-
Patent number: 8685916Abstract: The embodiments provide prodrug compounds of Formulae I-XV. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug compound of Formulae I-XV that provides controlled release of an opioid. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of an opioid from the prodrug so as to attenuate enzymatic cleavage of the prodrug.Type: GrantFiled: March 8, 2012Date of Patent: April 1, 2014Assignee: Signature Therapeutics, Inc.Inventors: Thomas E. Jenkins, Craig O. Husfeld